Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 8, 2009, Pages 1240-1244

  Beigel, Florian ^a   Jürgens, Matthias ^a   Filik, Levent ^b   Bader, Lutz ^c   Lück, Christian ^d   Göke, Burkhard ^a   Ochsenkühn, Thomas ^a   Brand, Stephan ^a   Seiderer, Julia ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BASKENT UNIVERSITY   (Turkey)

^c UNIVERSITY OF MUNICH   (Germany)

^d DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Crohn's disease; Infliximab; Legionella pneumophila

Indexed keywords

AZATHIOPRINE; INFLIXIMAB; MESALAZINE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PREDNISOLONE;

ABDOMINAL PAIN; ADULT; ANTIGEN DETECTION; ARTICLE; AUSCULTATION; CASE REPORT; CROHN DISEASE; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; FATIGUE; FEVER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEGIONNAIRE DISEASE; LEUKOCYTE COUNT; MALE; NUCLEAR MAGNETIC RESONANCE; POLYMERASE CHAIN REACTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SYNCOPE; WEIGHT REDUCTION;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; CROHN DISEASE; DRUG THERAPY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEGIONELLA PNEUMOPHILA; LEGIONNAIRES' DISEASE; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 70349492472     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20866     Document Type: Article

References (24)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al, ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;35:1541-1549.
2. Hanauer S, Sandborn W, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-333.
3. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005. 8;353:2462-2476.
4. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
5. Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-155.
6. Moiton MP, Richez C, Dumoulin C, et al. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections. Clin Microbiol Infect. 2006;12:1151-1153.
7. Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore). 2005;84:291-302.
8. Strangfeld A, Listing J. Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006; 20:1181-1195.
9. Cohen RD, Bowie WR, Enns R, et al. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax. 2007;62:1013-1014
10. Tubach F, Ravaud P, Salmon-Ceron D, et al. Recherce Axee sur la Tolerance des Biotherapies Group. Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists. Clin Infect Dis. 2006;43:e95-100.
11. Diederen BM. Legionella spp. and Legionnaires' disease. J Infect. 2008;56:1-12.
12. Peyrin-Biroulet L, Deltenre P, de Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-ontrolled trials. Clin Gastroenterol Hepatol. 2008;6: 644-653.
13. Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol. 2006;22:30-43.
14. Strangfeld A, Listing J. Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006; 20:1181-1195.
15. Winthrop KL. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol. 2006;2:602-610.
16. Mancini G, Erario L, Gianfreda R, et al. Tuberculosis and Legionella pneumophila pneumonia in a patient receiving anti-tumour necrosis factor-alpha (anti-TNF-alpha) treatment. Clin Microbiol Infect. 2007;13: 1036-1037.
17. Hawn TR, Berrington WR, Smith IA, et al. Altered inflammatory responses in TLR5-deficient mice infected with Legionella pneumophila. J Immunol. 2007;179:6981-6987.
18. Nara C, Tateda K, Matsumoto T, et al. Legionella-induced acute lung injury in the setting of hyperoxia: protective role of tumour necrosis factor-alpha. J Med Microbiol. 2004;53:727-733.
19. Chang CC, Chung CL, Huang CL, et al. Legionnaires' disease in a patient with rheumatoid arthritis. J Microbiol Immunol Infect. 2001;34: 76-78.
20. Schmidt T, Pfeiffer A, Erhet W, et al. Legionella infection of the colon presenting as acute attack of ulcerative colitis. Gastroenterology. 1989; 97:751-755.
21. McDonald KS, Faoagali JL, Tait GB, et al. Legionnaires' disease in a patient with polymyositis. N Z Med J. 1980;91:451-452.
22. Matsunaga K, Klein TW, Friedman H, et al. Epigallocatechin gallate, a potential immunomodulatory agent of tea components, diminishes cigarette smoke condensate-induced suppression of anti-Legionella pneumophila activity and cytokine responses of alveolar mcrophages. Clin Diagn Lab Immunol. 2002;9:864-871.
23. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007;26:747-756.
24. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.